Article info

Download PDFPDF
Tolerance and safety of rapid 2-hour infusion of rituximab in patients with kidney-affecting autoimmune diseases and glomerulonephritides: a single-centre experience

Authors

  • Jan Miroslav Hartinger Institute of Pharmacology, Department of Clinical Pharmacology and Pharmacy, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic PubMed articlesGoogle scholar articles
  • Veronika Satrapová Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic PubMed articlesGoogle scholar articles
  • Zdenka Hrušková Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic PubMed articlesGoogle scholar articles
  • Vladimír Tesař Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic PubMed articlesGoogle scholar articles
  1. Correspondence to Jan Miroslav Hartinger, Farmakologický ústav, Univerzita Karlova v Praze 1 lekarska fakulta, Prague 12800, Czech Republic; hartinger.jan{at}vfn.cz
View Full Text

Citation

Hartinger JM, Satrapová V, Hrušková Z, et al
Tolerance and safety of rapid 2-hour infusion of rituximab in patients with kidney-affecting autoimmune diseases and glomerulonephritides: a single-centre experience

Publication history

  • Received November 17, 2017
  • Revised January 11, 2018
  • Accepted February 6, 2018
  • First published February 28, 2018.
Online issue publication 
June 28, 2019

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.